HeartBeam Ranked Second Globally in Portable ECG Innovation

HeartBeam has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's Total Cardiac Intelligence report. The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. This recognition highlights HeartBeam's growing influence in the next generation of cardiac monitoring technology and underscores the rapid maturation of the company's proprietary synthesis-ECG system.

The company's intellectual property foundation is a major reason for its high placement in the global rankings. HeartBeam's proprietary system captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain comprehensive cardiac data outside traditional medical facilities. The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead electrocardiogram acquired from 5 electrodes.

The device is designed for use by adult patients in either clinical settings or at home, though it does not conduct cardiac analysis and requires manual interpretation by healthcare professionals. For full safety information, users can refer to the complete instructions available through the company's resources. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while the 12-Lead ECG synthesis software remains under FDA review.

The company holds over 20 issued patents related to technology enablement, positioning it as a significant player in the evolving landscape of remote cardiac care. This recognition comes as the medical technology sector increasingly focuses on developing solutions that can deliver actionable heart intelligence outside traditional healthcare facilities. The platform technology is designed for portable devices that can be used wherever the patient is located, potentially transforming how cardiac conditions are detected and monitored.

Additional information about the company's developments is available through various investor resources and regulatory filings. The recognition by PatentVest's comprehensive analysis, accessible at https://ibn.fm/ZuLCr, validates HeartBeam's innovative approach to cardiac diagnostics and its potential impact on improving access to cardiac care through portable technology solutions.